A micelle-hydrogel composite for the delivery of growth factors in regenerative diseases
A micelle-hydrogel composite for the delivery of growth factors in regenerative diseases
Salah Moradi,1Rafieh Alizadeh,2,*
1. Department of Life Science Engineering, Faculty of New Science and Technology, University of Tehran, Tehran, Iran 2. ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Introduction: Anosmia is the inability to smell or loss of the sense of smell. It can
reduce your ability to detect the smell of smoke, gas leaks, or spoiled
food, as well as hinder the quality of life related to social
interactions and feelings of well-being. In the current study, a drug
delivery composite was designed to cure anosmia and its efficiency in
delivering transforming growth factor alpha (TGF-α) and transforming
growth factor beta 1 (TGF-β1) to the nasal cavity was evaluated. Bovine
serum albumin (BSA) was used as a model protein for encapsulation into
Poloxamers 407 micelles. For the optimization of the BSA-micelle
formulation, a two-parameter five-level central composite design (CCD)
was applied. The BSA-micelle was optimized with a particle size of
41 nm, drug loading of 8%, and _encapsulation efficiency of 74%_.
Further, the BSA-micelle was characterized by FESEM, TEM, and FTIR. The
analysis of release profile suggested high-paced free BSA release
compared to the gradual and prolonged release of BSA-micelle/hydrogel
and BSA-micelles. The cytotoxicity assay demonstrated the safety of
TGF-α and TGF-β1-micelles/hydrogel. Moreover, it was observed that
TGF-α and TGF-β1 within the hydrogels promote cellular viability and
human olfactory ectomesenchymal stem cell OE-MSCs proliferation. In
conclusion, According to the results of our study, the TGF-α and
TGF-β1-micelle/hydrogel-based delivery system provides a suitable
alternative for anosmia treatment..